Cargando…

Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model

The objective of the study is to validate intravascular quantitative echogenicity as a surrogate for molecular weight assessment of poly-l-lactide-acid (PLLA) bioresorbable scaffold (Absorb BVS, Abbott Vascular, Santa Clara, California). We analyzed at 9 time points (from 1- to 42-month follow-up) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Campos, Carlos M., Ishibashi, Yuki, Eggermont, Jeroen, Nakatani, Shimpei, Cho, Yun Kyeong, Dijkstra, Jouke, Reiber, Johan H. C., Sheehy, Alexander, Lane, Jennifer, Kamberi, Marika, Rapoza, Richard, Perkins, Laura, Garcia-Garcia, Hector M., Onuma, Yoshinobu, Serruys, Patrick W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368838/
https://www.ncbi.nlm.nih.gov/pubmed/25627777
http://dx.doi.org/10.1007/s10554-015-0591-4
_version_ 1782362699149082624
author Campos, Carlos M.
Ishibashi, Yuki
Eggermont, Jeroen
Nakatani, Shimpei
Cho, Yun Kyeong
Dijkstra, Jouke
Reiber, Johan H. C.
Sheehy, Alexander
Lane, Jennifer
Kamberi, Marika
Rapoza, Richard
Perkins, Laura
Garcia-Garcia, Hector M.
Onuma, Yoshinobu
Serruys, Patrick W.
author_facet Campos, Carlos M.
Ishibashi, Yuki
Eggermont, Jeroen
Nakatani, Shimpei
Cho, Yun Kyeong
Dijkstra, Jouke
Reiber, Johan H. C.
Sheehy, Alexander
Lane, Jennifer
Kamberi, Marika
Rapoza, Richard
Perkins, Laura
Garcia-Garcia, Hector M.
Onuma, Yoshinobu
Serruys, Patrick W.
author_sort Campos, Carlos M.
collection PubMed
description The objective of the study is to validate intravascular quantitative echogenicity as a surrogate for molecular weight assessment of poly-l-lactide-acid (PLLA) bioresorbable scaffold (Absorb BVS, Abbott Vascular, Santa Clara, California). We analyzed at 9 time points (from 1- to 42-month follow-up) a population of 40 pigs that received 97 Absorb scaffolds. The treated regions were analyzed by echogenicity using adventitia as reference, and were categorized as more (hyperechogenic or upperechogenic) or less bright (hypoechogenic) than the reference. The volumes of echogenicity categories were correlated with the measurements of molecular weight (Mw) by gel permeation chromatography. Scaffold struts appeared as high echogenic structures. The quantification of grey level intensity in the scaffold-vessel compartment had strong correlation with the scaffold Mw: hyperechogenicity (correlation coefficient = 0.75; P < 0.01), upperechogenicity (correlation coefficient = 0.63; P < 0.01) and hyper + upperechogenicity (correlation coefficient = 0.78; P < 0.01). In the linear regression, the R(2) for high echogenicity and Mw was 0.57 for the combination of hyper and upper echogenicity. IVUS high intensity grey level quantification is correlated to Absorb BVS residual molecular weight and can be used as a surrogate for the monitoring of the degradation of semi-crystalline polymers scaffolds. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10554-015-0591-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4368838
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-43688382015-03-26 Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model Campos, Carlos M. Ishibashi, Yuki Eggermont, Jeroen Nakatani, Shimpei Cho, Yun Kyeong Dijkstra, Jouke Reiber, Johan H. C. Sheehy, Alexander Lane, Jennifer Kamberi, Marika Rapoza, Richard Perkins, Laura Garcia-Garcia, Hector M. Onuma, Yoshinobu Serruys, Patrick W. Int J Cardiovasc Imaging Original Paper The objective of the study is to validate intravascular quantitative echogenicity as a surrogate for molecular weight assessment of poly-l-lactide-acid (PLLA) bioresorbable scaffold (Absorb BVS, Abbott Vascular, Santa Clara, California). We analyzed at 9 time points (from 1- to 42-month follow-up) a population of 40 pigs that received 97 Absorb scaffolds. The treated regions were analyzed by echogenicity using adventitia as reference, and were categorized as more (hyperechogenic or upperechogenic) or less bright (hypoechogenic) than the reference. The volumes of echogenicity categories were correlated with the measurements of molecular weight (Mw) by gel permeation chromatography. Scaffold struts appeared as high echogenic structures. The quantification of grey level intensity in the scaffold-vessel compartment had strong correlation with the scaffold Mw: hyperechogenicity (correlation coefficient = 0.75; P < 0.01), upperechogenicity (correlation coefficient = 0.63; P < 0.01) and hyper + upperechogenicity (correlation coefficient = 0.78; P < 0.01). In the linear regression, the R(2) for high echogenicity and Mw was 0.57 for the combination of hyper and upper echogenicity. IVUS high intensity grey level quantification is correlated to Absorb BVS residual molecular weight and can be used as a surrogate for the monitoring of the degradation of semi-crystalline polymers scaffolds. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10554-015-0591-4) contains supplementary material, which is available to authorized users. Springer Netherlands 2015-01-28 2015 /pmc/articles/PMC4368838/ /pubmed/25627777 http://dx.doi.org/10.1007/s10554-015-0591-4 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Paper
Campos, Carlos M.
Ishibashi, Yuki
Eggermont, Jeroen
Nakatani, Shimpei
Cho, Yun Kyeong
Dijkstra, Jouke
Reiber, Johan H. C.
Sheehy, Alexander
Lane, Jennifer
Kamberi, Marika
Rapoza, Richard
Perkins, Laura
Garcia-Garcia, Hector M.
Onuma, Yoshinobu
Serruys, Patrick W.
Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model
title Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model
title_full Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model
title_fullStr Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model
title_full_unstemmed Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model
title_short Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model
title_sort echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368838/
https://www.ncbi.nlm.nih.gov/pubmed/25627777
http://dx.doi.org/10.1007/s10554-015-0591-4
work_keys_str_mv AT camposcarlosm echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT ishibashiyuki echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT eggermontjeroen echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT nakatanishimpei echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT choyunkyeong echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT dijkstrajouke echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT reiberjohanhc echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT sheehyalexander echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT lanejennifer echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT kamberimarika echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT rapozarichard echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT perkinslaura echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT garciagarciahectorm echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT onumayoshinobu echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel
AT serruyspatrickw echogenicityasasurrogateforbioresorbableeverolimuselutingscaffolddegradationanalysisat1361218243036and42monthfollowupinaporcinemodel